LAB/B: Margins held strong despite sales decline, with recovery and growth initiatives set for 2026

About this update from Genomma Lab Internacional Sab De Cv Class B

2025 saw a deliberate inventory normalization in Mexico, leading to lower sales but resilient margins and strong cash flow. Productivity gains and disciplined cost management support a positive 2026 outlook, with gradual top-line recovery and EBITDA margin guidance of 23%-23.5%. Based on This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Genomma Lab Internacional Sab De Cv Class B